Enovix Earnings Call: Record Revenue, Rising Risks

Enovix Corporation ((ENVX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Enovix’s latest earnings call balanced optimism with caution as management highlighted record revenue, improving margins, and a cash war chest of $621 million, while acknowledging technical hurdles and timing risks in smartphones. Investors heard a story of growing commercial traction in defense, drones, and smart eyewear, but also a reminder that qualification and manufacturing execution will dictate the pace of value creation.

Record Revenue Underscores Commercial Progress

Enovix posted Q4 2025 revenue of $11.3 million, a record quarter that grew 16% year over year and topped the high end of guidance at $10.5 million. Full‑year 2025 revenue reached a record $31.8 million, up 38% from the prior year, signaling early but tangible traction across its target markets.

Margin Expansion on Defense Mix

Non‑GAAP gross profit in Q4 was $2.9 million, translating into a non‑GAAP gross margin of about 26% as scale and mix improved. For 2025, non‑GAAP gross margin climbed to 23%, helped by higher volumes and a shift toward higher‑margin defense batteries following the April 2025 asset acquisition.

Cash Rich Balance Sheet and Buyback Flexibility

The company ended the year with roughly $621 million in cash, cash equivalents, and marketable securities, providing a sizable runway for R&D and manufacturing build‑out. Management underscored this balance‑sheet strength by authorizing a share repurchase program, giving flexibility to return capital while continuing to invest.

Smartphone Engagement Deepens but Testing Gap Remains

Enovix has now engaged with seven of the top eight global smartphone makers and is in formal qualification with its lead customer, Honor, since Q3 2025. Internal testing suggests the firm is on track to exceed the 1,000‑cycle requirement at 0.2C, which boosts confidence in the architecture and supports longer‑term mobile integration planning.

Smartphone Cycle-Life Shortfall at 0.7C

Despite progress at 0.2C, the company acknowledged its batteries are not yet meeting the more demanding 0.7C accelerated cycle‑life tests used by smartphone OEMs. Because no 100% silicon‑anode smartphone battery has previously been qualified, test protocols are still evolving, creating a risk that technical fixes and extra testing could extend timelines.

Uncertain Timeline for Large-Scale Smartphone Ramp

Management described three potential paths forward: customer acceptance of 0.2C testing, a newly agreed accelerated protocol, or electrochemistry changes to pass 0.7C. These choices introduce timing uncertainty, and the company now sees significant smartphone volumes as possible in late 2026 but more likely in 2027 depending on how qualification shakes out.

Smart Eyewear Emerges as Faster Commercial Beachhead

With smartphone timelines in flux, smart eyewear is positioned as a nearer‑term revenue driver thanks to lower qualification hurdles and less demanding cycle‑life thresholds. Enovix is preparing capacity to support a lead smart eyewear customer and expects its first high‑volume smart eyewear shipments in the second half of 2026, targeting a battery market that could surpass $400 million by 2030.

Defense and Drone Pipelines Build Scale

Defense shipments remained Enovix’s largest revenue contributor in 2025, with naval munitions dominating Q4 output and validating high‑value use cases. The company now sees a roughly $100 million global defense pipeline with multiple Tier 1 contractors and is also eyeing a drone battery opportunity it estimates at about $1.5 billion this year.

Energy Density Roadmap Supports Premium Use Cases

Enovix highlighted internal testing of a high‑energy drone cell at about 342 Wh/kg, already competitive in demanding aerial missions. The roadmap targets more than 400 Wh/kg in next‑generation silicon‑anode products, which would support longer flight times and expanded missions, strengthening the value proposition in drones and defense.

Manufacturing Muscle and Fab2 Progress

To support scale‑up, the company added a Head of Global Manufacturing and a Head of Advanced Manufacturing Engineering, signaling a pivot from lab to factory discipline. Fab2 performance is improving, with most process steps now achieving around 80% or better yields, narrowing the gap to commercial‑scale economics.

Laser Dicing Bottleneck Limits Throughput

Zone 1 laser dicing was identified as the main constraint on Fab2 throughput despite yields nearing 80% in Q4 and running around that level quarter‑to‑date. Management is working on process optimization and exploring alternative dicing technologies, but resolving this bottleneck is essential to unlocking higher production rates and revenue.

Process Changes Could Trigger Requalification Risk

Any significant shift in dicing technology or other key process steps will require careful customer communication. In many cases, such changes may force full or partial requalification of products, adding testing time and potentially delaying commercial ramps even as throughput improves.

Continuing Operating Losses and Cash Burn

Despite revenue and margin gains, Enovix remains deeply in the red, with a Q4 non‑GAAP loss from operations of $28.9 million, though this was better than guidance. For Q1 2026, management guided to a non‑GAAP operating loss between $29 million and $32 million, signaling ongoing heavy investment in qualification and manufacturing readiness.

Seasonality and Revenue Concentration Weigh on Near Term

Q1 2026 revenue guidance of $6.5 million to $7.5 million implies a sharp drop from Q4’s $11.3 million, driven by seasonal factors and the timing of defense programs. The call highlighted that revenue remains concentrated in defense and industrial segments for now, leaving near‑term results sensitive to program schedules.

Staggered CapEx and Limited Long-Term Capacity Visibility

Equipment delivery and vendor payment timing made Q4 capital outlays lower than previously expected, with most payments shifting into the first half of 2026 and Q1 CapEx projected at $9 million to $11 million. While the Korea facility offers room to scale, management did not provide multi‑year CapEx or megawatt‑hour capacity targets, creating modeling uncertainty about the pace of the ramp.

Forward Guidance Highlights Growth and Investment Trade-Offs

Looking ahead to Q1 2026, Enovix guided to $6.5 million to $7.5 million of revenue, a non‑GAAP operating loss of $29 million to $32 million, and CapEx of $9 million to $11 million as equipment payments shift into the first half of the year. This comes after a Q4 that beat on revenue and operating loss guidance, closed 2025 with 23% full‑year non‑GAAP gross margin, and left the company sitting on $621 million of cash while advancing defense pipelines and high‑energy drone cells.

Enovix’s earnings call painted the picture of a company moving from promise to early proof points, with record revenue, higher margins, and robust liquidity offset by smartphone qualification uncertainty and manufacturing bottlenecks. For investors, the story now hinges on how quickly management can resolve testing and throughput issues, convert defense and smart eyewear pipelines into durable revenue, and narrow losses without diluting its strong balance sheet.